Connect with us

coronavirus

A public dialogue on media and digital tools for the second online forum of the Anna Lindh Foundation Virtual Marathon

SHARE:

Published

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

The Anna Lindh Foundation Virtual Marathon for Dialogue in the EuroMed region (VM) gathers activities of ALF civil society Network and partner organizations to take place for 42 days until 29 June for 63 online events. The VM aims to highlight the importance of the Intercultural Dialogue to build sustainable societies in the EuroMed region, considering the challenges and opportunities brought about by the COVID-19 pandemic.

Towards this goal, in addition to a rich program of civil society and partner-led activities, a series of Weekly Public Virtual Dialogues organized by the Anna Lindh Foundation was designed to stimulate a broad conversation and reflection on significant issues impacting mutual perceptions between people in the region and joint action to address social and cultural challenges affecting societies North, South, East and West of the Mediterranean.

Media and Digital Tools were the main themes of the second Weekly Public Dialogue, 'Digital Threats and Opportunities'. The sudden digital shift driven by the COVID-19 pandemic has made more visible challenges and threats related to diversity and mutual perceptions through increased discrimination, hate speech, racial profiling, and fake news on social media. At the same time, digital technology use driven by the pandemic has lifted barriers and expanded accessibility, inclusivity, and equitable participation in knowledge-sharing online platforms. Digitalization in this context has also offered opportunities shedding light on the crucial role of civil society organizations in acting as information channels and first responders since the pandemic outbreak.

Advertisement

Aissam Benaissa (Connect NordAfrika) moderated the event, which saw the participation of essential network members and stakeholders, including civil society representatives, youth, educators, media, and institutional partners, such as Vesna Loncaric (member of the Cabinet of Ms. Dubravka Suica, EU Vice President, Commissioner for Democracy and Demography); Sid El-Mohri (YMV participant, Algeria); Nadia Henni-Moulai (Journaliste politique Jeune Afrique): Viktória Mihalkó (Anthropolis Association, Hungary); Rachida Mohtaram El Alaoui (Association Marocaine des petits débrouillards); Lurdes Vidal (IEM, author of the ALF 2021 Report); Michael Bush (Education and Society, British Council).

Based on principles of active listening, formulating and responding to arguments, and constructively incorporating feedback in the formulation of recommendations, suggestions, and action points (including policy recommendations), the discussion between the panelists led to an open conversation with the public. Vesna Loncaric highlighted the importance of the Barcelona Process, considered an antecedent of the Union for the Mediterranean and of the Euro-Mediterranean free trade area: "During 25 years, the Barcelona Process has been an important laboratory for intercultural action and dialogue with civil society and youth for a more integrated, peaceful and inclusive Mediterranean"; Vesna Loncaric also talked about the importance of social media for dialogue "Social media strengthens links among people across the world, creating an environment for learning and understanding, let's take advantage of this wonderful opportunity and realize that the world belongs equally to each and every one of us!".

Sid El-Mohri talked about the fundamental importance of Freedom of speech, "a crucial component in effective and constructive dialogue, especially interculturally. Compromising the Freedom of speech challenged the dialogue and its quality by individuals who can express themselves, their ideas, opinions, and emotions."

Advertisement

Nadia Henni-Moulai mentioned the risks of rising populism and radicalization "We need to empower young people to think critically. Digital is good, but not enough; it is necessary to get back to the field." During the webinar, also came out different questions based on the topic of the event, such as the development of a new language (or culture) based on the digital "grammar" and a new modus operandi (i.e., algorithms) which involves a re-thinking of the Intercultural Dialogue. Other aspects were linked to making our system more inclusive and tolerant, starting from the lessons from this pandemic and new forms of intercultural engagement on social media as a key vector to organize. This means cross-cultural solidarity messages, collaborations to help marginalized communities, artistic performances to connect people. The analysis of the priority measures on the intercultural dialogue agenda for a post-COVID-19 digital inclusive community was another question for debate. The negative pandemic impacts perpetuated online such as xenophobia, racism, hate speech, and other forms of intolerance raised severe challenges about the intercultural dialogue guiding principles. Moreover, another relevant point was about the role that can be played by digital tools to provide for a better quality of cross-cultural reporting.

A relevant resolution backing the debate was the JOINT COMMUNICATION TO THE EUROPEAN PARLIAMENT, THE EUROPEAN COUNCIL, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS: Tackling COVID-19 disinformation - Getting the facts right. More information on the resolution.

The Anna Lindh Foundation is an international organization, born in 2004, working from the Mediterranean to promote intercultural and civil society dialogue in the face of growing mistrust and polarisation. Headquartered in Alexandria, ALF has coordinators and management staff based across more than 40 countries ALF.

Further event are taking place online in the 42 countries of the ALF network: https://www.annalindhfoundation.org/anna-lindh-foundation-virtual-marathon-dialogue-euromed https://www.facebook.com/groups/3909240492445240

coronavirus

US-EU agenda for beating the global pandemic: Vaccinating the world, saving lives now, and building back better health security

Published

on

Vaccination is the most effective response to the COVID pandemic. The United States and the EU are technological leaders in advanced vaccine platforms, given decades of investments in research and development.

It is vital that we aggressively pursue an agenda to vaccinate the world. Co-ordinated US and EU leadership will help expand supply, deliver in a more coordinated and efficient manner, and manage constraints to supply chains. This will showcase the force of a Transatlantic partnership in facilitating global vaccination while enabling more progress by multilateral and regional initiatives.

Building on the outcome of the May 2021 G20 Global Health Summit, the G7 and US-EU Summits in June, and on the upcoming G20 Summit, the US and the EU will expand cooperation for global action toward vaccinating the world, saving lives now, and building better health security.  

Advertisement

Pillar I: A Joint EU/US Vaccine Sharing Commitment: the United States and the EU will share doses globally to enhance vaccination rates, with a priority on sharing through COVAX and improving vaccination rates urgently in low and lower-middle income countries. The United States is donating over 1.1 billion doses, and the EU will donate over 500 million doses. This is in addition to the doses we have financed through COVAX.

We call for nations that are able to vaccinate their populations to double their dose-sharing commitments or to make meaningful contributions to vaccine readiness. They will place a premium on predictable and effective dose-sharing to maximize sustainability and minimize waste.

Pillar II: A Joint EU/US Commitment to Vaccine Readiness: the United States and the EU will both support and coordinate with relevant organisations for vaccine delivery, cold chain, logistics, and immunization programs to translate doses in vials into shots in arms. They will share lessons learned from dose sharing, including delivery via COVAX, and promote equitable distribution of vaccines.

Advertisement

Pillar III: A Joint EU/US partnership on bolstering global vaccine supply and therapeutics: the EU and the United States will leverage their newly launched Joint COVID-19 Manufacturing and Supply Chain Taskforce to support vaccine and therapeutic manufacturing and distribution and overcome supply chain challenges. Collaborative efforts, outlined below, will include monitoring global supply chains, assessing global demand against the supply of ingredients and production materials, and identifying and addressing in real time bottlenecks and other disruptive factors for global vaccine and therapeutics production, as well as coordinating potential solutions and initiatives to boost global production of vaccines, critical inputs, and ancillary supplies.

Pillar IV: A Joint EU/US Proposal to achieve Global Health Security. The United States and the EU will support the establishment of a Financial Intermediary Fund (FIF) by the end of 2021 and will support its sustainable capitalization.  The EU and United States will also support global pandemic surveillance, including the concept of a global pandemic radar. The EU and the United States, through HERA and the Department of Health and Human Services Biomedical Advanced Research and Development Authority, respectively, will cooperate in line with our G7 commitment to expedite the development of new vaccines and make recommendations on enhancing the world's capacity to deliver these vaccines in real time. 

We call on partners to join in establishing and financing the FIF to support to prepare countries for COVID-19 and future biological threats.

Pillar V: A Joint EU/US/Partners Roadmap for regional vaccine production. The EU and the United States will coordinate investments in regional manufacturing capacity with low and lower-middle income countries, as well as targeted efforts to enhance capacity for medical countermeasures under the Build Back and Better World infrastructure and the newly established Global Gateway partnership. The EU and the United States will align efforts to bolster local vaccine manufacturing capacity in Africa and forge ahead on discussions on expanding the production of COVID-19 vaccines and treatments and ensure their equitable access.

We call on partners to join in supporting coordinated investments to expand global and regional manufacturing, including for mRNA, viral vector, and/or protein subunit COVID-19 vaccines.

More information

Joint statement on the launch of the joint COVID-19 Manufacturing and Supply Chain Taskforce

Continue Reading

coronavirus

Coronavirus: 200th EU disinfection robot delivered to European hospital, a further 100 confirmed

Published

on

On 21 September, the Commission delivered the 200th disinfection robot – to Consorci Corporació Sanitària Parc Taulí hospital in Barcelona. The robots, donated by the Commission, help sanitize COVID-19 patient rooms and are part of the Commission's action to supply hospitals across the EU to help them cope with the effects of the coronavirus pandemic. Further to these initial 200 robots announced in November last year, the Commission secured the purchase an additional 100, bringing the total donations to 300.

A Europe fit for the Digital Age Executive Vice President for Margrethe Vestager, said: “Assisting member states overcome the challenges of the pandemic continues to be a number one priority and these donations – a very tangible form of support – are a prime example of what can be achieved. This is European solidarity in action and I am pleased to see the Commission can go the extra mile in donating an additional 100 disinfection robots to hospitals in need.”

Twenty-five disinfection robots have already been working night and day across Spain since February to help tackle the spread of the coronavirus. Nearly every EU Member State has now received at least one disinfection robot, which disinfects a standard patient room in under 15 minutes, alleviating hospital staff and offering them and their patients greater protection against potential infection. This action is made possible through the Emergency Support Instrument and the devices are supplied by Danish company UVD robots, which won an emergency procurement tender.

Advertisement

Continue Reading

coronavirus

Coronavirus: Commission signs contract for the supply of a monoclonal antibody treatment

Published

on

The Commission has signed a joint procurement framework contract with the pharmaceutical company Eli Lilly for the supply of a monoclonal antibody treatment for coronavirus patients. This marks the latest development in this first portfolio of five promising therapeutics announced by the Commission under the EU COVID-19 Therapeutics Strategy in June 2021. The medicine is currently under rolling review by the European Medicines Agency. 18 member states have signed up to the joint procurement for the purchase of up to 220,000 treatments.

Health and Food Safety Commissioner Stella Kyriakides said: “Over 73% of the EU adult population is now fully vaccinated, and this rate will still increase. But vaccines cannot be our only response to COVID-19. People still continue to be infected and fall ill. We need to continue our work to prevent illness with vaccines and at the same time ensure that we can treat it with therapeutics. With today's signature, we conclude our third procurement and deliver on our commitment under the EU Therapeutics Strategy to facilitate access to state-of-the-art medicines for COVID-19 patients.”

While vaccination remains the strongest asset both against the virus and its variants, therapeutics play a critical role in the COVID-19 response. They help to save lives, speed up recovery time, reduce the length of hospitalisation and ultimately ease the burden of health care systems.

Advertisement

The product from Eli Lilly is a combination of two monoclonal antibodies (bamlanivimab and etesevimab) for the treatment of coronavirus patients who do not require oxygen but are at high risk of severe COVID-19. Monoclonal antibodies are proteins conceived in the laboratory that mimic the immune system's ability to fight the coronavirus. They fuse to the spike protein and thus block the virus's attachment to the human cells.

Under the EU Joint Procurement Agreement, the European Commission has concluded until now nearly 200 contracts for different medical countermeasures with a cumulative value of over €12 billion. Under the joint procurement framework contract concluded with Eli Lilly, member states can purchase the combination product bamlanivimab and etesevimab if and when needed, once it has received either a conditional marketing authorisation at EU level from the European Medicines Agency or an emergency use authorisation in the member state concerned.

Background

Advertisement

Today's joint procurement contract follows the contract signed with Roche for the product REGN-COV2, a combination of Casirivimab and Imdevimab, on 31 March 2021 and the contract with Glaxo Smith Kline on 27 July 2021 for the supply of sotrovimab (VIR-7831), developed in collaboration with VIR biotechnology.

The EU Strategy on COVID-19 Therapeutics, adopted on 6 May 2021, aims to build a broad portfolio of COVID-19 therapeutics with the goal of having three new therapeutics available by October 2021 and possibly two more by the end of the year. It covers the full lifecycle of medicines from research, development, selection of promising candidates, fast regulatory approval, manufacturing and deployment to final use. It will also coordinate, scale-up and ensure that the EU acts together in ensuring access to therapeutics via joint procurements.

The Strategy forms part of a strong European Health Union, using a coordinated EU approach to better protect the health of our citizens, equip the EU and its Member States to better prevent and address future pandemics, and improve resilience of Europe's health systems. Focusing on the treatment of patients with COVID-19, the Strategy works alongside the successful EU Vaccines Strategy, through which safe and effective vaccines against COVID-19 have been authorised for use in the EU to prevent and reduce transmission of cases, as well as hospitalisation rates and deaths caused by the disease.

On 29 June 2021, the strategy delivered its first outcome, with the announcement of five candidate therapeutics that could soon be available to treat patients across the EU. The five products are in an advanced stage of development and have a high potential to be among the three new COVID-19 therapeutics to receive authorization by October 2021, the target set under the strategy, provided the final data demonstrate their safety, quality and efficacy.

Global co-operation on therapeutics is crucial and a key component of our strategy. The Commission is committed to working together with international partners on COVID-19 therapeutics and make them available globally. The Commission is also exploring how to support the enabling environment for manufacturing health products, while strengthening research capacity in partner countries around the globe.

More information

EU Therapeutics Strategy

Coronavirus response

Safe COVID-19 vaccines for Europeans

Continue Reading
Advertisement
Advertisement
Advertisement

Trending